-
Product Insights
Proto Oncogene Tyrosine Protein Kinase Receptor Ret – Drugs In Development, 2023
Global Markets Direct’s Proto Oncogene Tyrosine Protein Kinase Receptor Ret provides in depth analysis on Proto Oncogene Tyrosine Protein Kinase Receptor Ret targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pralsetinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Metastatic Uveal Melanoma Drug Details: Sitravatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Solid Tumor Drug Details: Dovitinib lactate (TKI258,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Gastrointestinal Stromal Tumor (GIST) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dovitinib Lactate in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dovitinib Lactate in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dovitinib Lactate in Metastatic Ovarian Cancer Drug Details: Dovitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Metastatic Hepatocellular Carcinoma (HCC) Drug...